RayBiotech and Venebio Group Form Strategic Partnership to Accelerate Drug Development Through Integrated Proteomics and Regulatory Expertise
核心洞察
RayBiotech Life, Inc. (搜索) and Venebio Group, LLC (搜索) have entered into a Master Services Agreement to combine proteomics (搜索) platforms with regulatory strategy expertise for drug and diagnostics development.
The collaboration integrates RayBiotech's biomarker (搜索) discovery services and high-throughput protein arrays with Venebio's regulatory planning and clinical trial design capabilities.
The partnership aims to provide customized services from biomarker (搜索)-driven trial design to clinical assay validation, helping life science companies navigate regulatory challenges more effectively.
RayBiotech Life, Inc. (搜索), a global leader in proteomics (搜索) and translational research tools, has announced a strategic collaboration with Venebio Group, LLC (搜索), a premier life sciences consultancy specializing in regulatory strategy and drug safety analytics. The partnership, formalized through a Master Services Agreement (MSA), aims to support drug and diagnostics developers by combining cutting-edge proteomics capabilities with regulatory expertise.
Strategic Integration of Complementary Capabilities
The collaboration brings together RayBiotech's proprietary proteomics (搜索) platforms and biomarker (搜索) discovery services with Venebio's deep domain expertise in regulatory planning, trial design, and evidence generation. This integration creates what Dr. Jarad Wilson, Associate Director of Business Development at RayBiotech, describes as "a powerful synergy between RayBiotech's cutting-edge technologies and Venebio's proven leadership in regulatory and clinical strategy."
The partnership specifically targets areas of high unmet medical need, with both companies committed to streamlining the development of impactful therapeutics and diagnostics. Venebio Group brings a strong track record of supporting biopharma innovators across every stage of development—from early discovery through post-market safety assessment and reporting.
Enhanced Service Portfolio
Under the new agreement, the companies will offer comprehensive support that leverages their respective strengths. RayBiotech's core offerings include high-throughput protein arrays, cytokine (搜索) profiling, and antibody development, while Venebio contributes regulatory insights and strategic guidance throughout the development process.
Catherine C. Vick, MS, President & CEO of Venebio Group, emphasized the complementary nature of the partnership, stating that "RayBiotech's capabilities in translational biomarker (搜索) discovery and clinical assay development are ideal complements to our consulting practice."
Customized Solutions for Regulatory Navigation
The collaboration will facilitate customized services ranging from biomarker (搜索)-driven trial design to clinical assay validation. This comprehensive approach is designed to enhance the ability of life science companies to navigate regulatory hurdles and demonstrate therapeutic value more effectively.
The partnership addresses a critical need in the life sciences sector, where companies often struggle to bridge the gap between innovative research capabilities and regulatory requirements. By combining RayBiotech's technical expertise in proteomics (搜索) with Venebio's regulatory strategy experience, the collaboration offers a more streamlined path from discovery to market.
Company Backgrounds
RayBiotech has established itself as a leader in proteomics (搜索) by providing cutting-edge tools and services that accelerate discovery in disease biology, biomarker (搜索) validation, and therapeutic development. The company's portfolio includes antibody arrays, ELISA kits, custom assay development, and central lab services for translational and clinical research.
Venebio Group, based in Virginia, operates as a prominent scientific consultancy dedicated to providing strategic support for pharmaceutical, biotechnology, and medical device entities. Their expertise encompasses regulatory affairs, clinical trial and observational study design, data science, pharmacovigilance, and market access strategies centered around high-impact therapies.